Literature DB >> 7616742

Clinical development plan: N-(4-hydroxyphenyl)retinamide.

G J Kelloff1, J A Crowell, C W Boone, V E Steele, R A Lubet, P Greenwald, D S Alberts, J M Covey, L A Doody, G G Knapp.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7616742

Source DB:  PubMed          Journal:  J Cell Biochem Suppl        ISSN： 0733-1959


× No keyword cloud information.
  6 in total

Review 1.  Chemoprevention of breast cancer with fenretinide.

Authors:  R Torrisi; A Decensi; F Formelli; T Camerini; G De Palo
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Fenretinide activates caspases and induces apoptosis in gliomas.

Authors:  V K Puduvalli; Y Saito; R Xu; G P Kouraklis; V A Levin; A P Kyritsis
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

Review 3.  Fenretinide and cancer prevention.

Authors:  R Torrisi; A Decensi
Journal:  Curr Oncol Rep       Date:  2000-05       Impact factor: 5.075

4.  One-Step, Low-Cost, Operator-Friendly, and Scalable Procedure to Synthetize Highly Pure N-(4-ethoxyphenyl)-retinamide in Quantitative Yield without Purification Work-Up.

Authors:  Silvana Alfei; Guendalina Zuccari
Journal:  Molecules       Date:  2022-06-06       Impact factor: 4.927

Review 5.  Breast cancer prevention trials using retinoids.

Authors:  Andrea Decensi; Davide Serrano; Bernardo Bonanni; Massimiliano Cazzaniga; Aliana Guerrieri-Gonzaga
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-01       Impact factor: 2.673

Review 6.  Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?

Authors:  Massimiliano Cazzaniga; Clara Varricchio; Chiara Montefrancesco; Irene Feroce; Aliana Guerrieri-Gonzaga
Journal:  J Biomed Biotechnol       Date:  2012-03-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.